Skip to main content

Table 4 Combination therapy with targets in downstream signaling pathways

From: Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Target

Representative compound*

Structure

Reference

MEK

Trametinib

[155, 156]

MEK

Selumetinib

[155,156,157]

MEK

PD0325901

[155]

AKT

Uprosertib (GSK2141795)

[158]

AKT

Capivasertib (AZD5363)

[158]

AXL

Cabozantinib

View full size image

[159]

AXL

DS-1205b

View full size image

[160]

AXL

Yuanhuadine (YD)

View full size image

[161]

AXL

Bemcentinib (R428)

[162]

ACK1

(R)-9b

[163, 164]

  1. *Osimertinib is a representative third-generation EGFR-TKI
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us